GET THE FULL COMPANY
ANALYSIS BUNDLE FOR
Ultralife
How did Ultralife reshape portable power?
The company launched the first long-lasting 9-volt lithium battery, changing expectations for smoke alarms and medical devices. Founded in 1991 in Newark, NY, Ultralife moved from niche battery maker to diversified provider of power and communications systems.
Ultralife grew by focusing on high-energy lithium-manganese dioxide chemistry, expanding into defense, medical and industrial markets. In 2025 the company reported $194,000,000 in revenues and operates two main segments: Battery and Energy Products and Communications Systems.
What is the brief history of Ultralife Company? It began as Ultralife Batteries Inc. in 1991 and evolved into a global specialist in batteries, energy storage and communications; see Ultralife Porter's Five Forces Analysis.
What is the Ultralife Founding Story?
Ultralife Corporation began on March 25, 1991, after a management-led buyout of Eastman Kodak’s Ultra Technologies battery division, targeting high-performance lithium battery needs overlooked by consumer-grade makers.
Founding Story
Bruce Jagid led the founding team of engineers and executives who turned Kodak’s lithium-manganese dioxide patents into a standalone company focused on professional, high-drain applications.
- Founded on March 25, 1991 via a management buyout from Eastman Kodak
- Core technology: patented lithium-manganese dioxide cells developed under Kodak
- Flagship product: 9-volt lithium battery aimed at specialized electronics
- Initial funding: private equity plus Kodak’s divested manufacturing assets in Newark, New York
Founders identified alkaline chemistry limits in long-duration, high-drain uses and used chemical-engineering and scale-up expertise to position Ultralife as a premium supplier amid rising portable-electronics demand; early production costs for lithium were higher than alkaline and Ni-Cd alternatives, shaping a premium pricing and niche market strategy.
Early financials and capacity: initial manufacturing utilized Kodak’s Newark plant, enabling first-year production scaling to support commercial launch; by the mid-1990s the company focused R&D and sales on professional/industrial segments, marking key milestones on the Ultralife timeline and the Ultralife Company history.
For related coverage of business model and revenue focus, see Revenue Streams & Business Model of Ultralife
Complete Ultralife Strategy Bundle
- 6 Full Frameworks, 1 Company – All Pre-Researched
- Each Framework Fully Sourced with Real Company Data
- Built for Strategy Courses, Case Studies & MBA Programs
- Adapt to Your Assignment – No Starting from Scratch
- 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's
What Drove the Early Growth of Ultralife?
Following its 1991 founding, Ultralife accelerated growth by going public in 1992 and reinvesting proceeds into manufacturing and rechargeable chemistries, then winning key defense contracts that shifted the company toward mission-critical government business.
Capital raise and IPO
Ultralife launched its NASDAQ IPO in 1992 under the symbol ULBI, securing capital to expand production capacity and diversify into rechargeable battery chemistries.
Entry into defense
By the mid-1990s Ultralife won major U.S. DoD contracts for the BA-5390 non-rechargeable lithium cell, establishing a reputation for reliable field communications power.
Product and segment expansion
The 2006 acquisition of McDowell Research added power supplies and amplifiers, creating the Communications Systems segment and enabling integrated solutions beyond cells.
Rebrand and European foothold
In 2008 the company rebranded to Ultralife Corporation; the 2011 acquisition of UK-based ABSL Power Solutions expanded presence into European defense and space markets.
These strategic moves—IPO funding, DoD BA-5390 contracts, the McDowell and ABSL acquisitions, and the 2008 rebrand—shifted Ultralife Company history from a battery-cell maker to an integrated power- and communications-systems provider, stabilizing revenue against government spending cycles; annual revenue grew from under $10 million in the early 1990s to over $120 million by 2014 as cited in historical filings. Read more on the company’s values and long-term strategy in Mission, Vision & Core Values of Ultralife
From PESTLE Factors to Full Strategy Bundle
- PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
- Every Strategic Angle Covered – Nothing Left to Research
- Pre-filled with Company-Specific Research
- No Missing Sections for Your Case Study
- One Download Covers Your Entire Company Analysis
What are the key Milestones in Ultralife history?
Ultralife Company history highlights technological milestones like ThinCell and Hi-Rate batteries, over 50 patents, a $12 million 2022 acquisition of Excell Battery Group, supply-chain shocks in 2022–2023 that cut gross margin to 21%, and a strategic pivot to medical and industrial markets boosting medical revenue 18% YoY by 2024 and operating margin to 8.5% by 2025.
| Year | Milestone |
|---|---|
| 2022 | Acquisition of Excell Battery Group for $12 million, adding high-performance pack engineering for oil, gas, and medical sectors. |
| 2022–2023 | Supply-chain disruptions and rising lithium and component costs squeezed gross margins to 21%. |
| 2024–2025 | Strategic pivot to medical/industrial markets drove medical revenue growth of 18% in 2024 and operating margins to 8.5% by 2025. |
Ultralife innovations include the ThinCell platform for energy-dense cells and the Hi-Rate series tailored to medical robotics, backed by over 50 patents in battery construction and power management.
ThinCell Technology
High energy density cell architecture improved volumetric efficiency for portable and wearable systems.
Hi-Rate Battery Series
Designed for surgical robotics and medical devices, delivering high discharge rates with thermal management.
Battery Pack Engineering
Excell acquisition added custom pack design capabilities for oil, gas, and healthcare applications.
Power Management Patents
Patented circuitry improved charge control and lifecycle performance across product lines.
Li‑Ion Defense Transition
Adaptation to new Li‑Ion standards secured roles in Land Warrior and Nett Warrior programs.
Product Diversification
Expansion into portable oxygen concentrators and surgical robotics reduced defense revenue concentration.
Challenges included raw material inflation and component shortages in 2022–2023, which compressed margins, and periodic defense procurement volatility that created lumpy revenue streams.
Supply-Chain Shock
Rising lithium and component prices increased COGS and reduced gross margin to 21% in 2023.
Defense Revenue Cyclicality
Dependence on episodic defense contracts prompted a strategic shift toward steady medical and industrial customers.
Integration Risk
Integrating Excell's engineering capabilities required operational realignment and capital deployment to scale medical product lines.
Standards Compliance
Meeting evolving Li‑Ion standards for defense demanded R&D investment and certification timelines.
Margin Recovery
Operational efficiencies and portfolio rebalancing improved operating margin to 8.5% by 2025.
Market Diversification
Shifting toward higher-margin medical markets delivered 18% medical revenue growth in 2024 and reduced sector-specific exposure.
Further reading on strategy and timeline is available in this article: Growth Strategy of Ultralife
Ultralife Business Model + Strategy Bundle
- Ideal for Essays, Case Studies & Slides
- Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
- Company-Specific Content Already Organized
- One Bundle Replaces Days of Independent Research
- Buy the Bundle Once. Use Across All Your Assignments
What is the Timeline of Key Events for Ultralife?
Timeline and Future Outlook: a concise Ultralife Company history tracing origins, major milestones and recent financial and strategic developments through 2025 and projected moves into 2026 and beyond, highlighting product evolution, acquisitions and AI-enabled power management initiatives.
| Year | Key Event |
|---|---|
| 1991 | Ultralife Batteries Inc. founded in Newark, NY after a Kodak buyout, marking the start of the company's origins and early years of development. |
| 1992 | Initial Public Offering on NASDAQ under the ticker ULBI, establishing public capital access for growth. |
| 1998 | Introduction of ThinCell battery technology for specialized electronics, a key Ultralife milestone in product evolution. |
| 2002 | Major expansion of U.S. military contracts for the BA-5390 battery series, strengthening government revenue streams. |
| 2006 | Acquisition of McDowell Research, signaling entry into tactical communications systems. |
| 2008 | Corporate rebrand to Ultralife Corporation to reflect diversified offerings across batteries and systems. |
| 2011 | Acquisition of ABSL Power Solutions, expanding presence into the UK and space market applications. |
| 2013 | Launch of the URB12400-U1-SMB lithium iron phosphate battery targeting medical carts and critical-care devices. |
| 2017 | Acquisition of Accutronics Ltd, strengthening European medical market presence and service capabilities. |
| 2022 | Purchase of Excell Battery Group for $12,000,000 to boost industrial engineering and manufacturing scale. |
| 2024 | Recorded a quarterly revenue exceeding $46,000,000 in Q3, the highest single-quarter revenue to date. |
| 2025 | Completed full integration of Excell operations and launched AI-enabled power management offerings, with a backlog of orders > $105,000,000. |
Commercial vs Government Mix
Management targets a shift to a 60-40 commercial-to-government revenue split as of 2026, aiming to improve margins and diversify Ultralife Corporation background.
AI-Enabled Power Management
2025 launch of AI-driven power management systems positions the company to offer predictive battery health and efficiency gains across tactical communications and industrial clients.
R&D: Solid-State and Next-Gen Cells
Leadership signaled investment into next-generation solid-state battery research to extend lifecycle and energy density for medical and defense applications.
Order Backlog and Growth Trajectory
With a 2025 backlog exceeding $105,000,000 and record quarterly revenue in 2024, analysts project steady operating margin expansion and sustained revenue growth through 2026 and beyond.
From Five Forces to Full Company Analysis
- Includes SWOT, PESTLE, BMC, BCG and 4P's
- Pre-Researched with Company-Specific Data
- Best Value for a Complete Analysis
- Ready to Adapt for Your Case Study
- Ready for Essays and Slidesd
- What is Competitive Landscape of Ultralife Company?
- What is Growth Strategy and Future Prospects of Ultralife Company?
- How Does Ultralife Company Work?
- What is Sales and Marketing Strategy of Ultralife Company?
- What are Mission Vision & Core Values of Ultralife Company?
- Who Owns Ultralife Company?
- What is Customer Demographics and Target Market of Ultralife Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.